BCBryan R. Conway

Bryan R. Conway

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bryan R. Conway has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association between Haptoglobin Gene Variants and Diabetic Nephropathy: Haptoglobin Polymorphism in Nephropathy Susceptibility

    by Bryan R. Conway, David A. Savage, Hugh R. Brady, Alexander P. Maxwell

    Background/Aims: The Hp1/Hp2 DNA polymorphism has previously been implicated in susceptibility to diabetic nephropathy in some but not all studies. In an attempt to clarify these conflicting findings, we conducted a case-control association study in a Caucasian population. Methods: We recruited 224 and 285 type 1 diabetic patients with (cases) and without (controls) nephropathy, respectively, from 2 centres based in Northern Ireland and the Republic of Ireland. Hp1/Hp2 genotyping was performed using a combination of long-range and multiplex PCR. Allele and genotype frequencies in cases and controls were compared using the χ2 test. Results: There was a statistically significant increase in the frequency of the Hp2 allele in cases compared to controls (65.6 vs. 58.6%, OR = 1.35, 95% CI: 1.04–1.76, p = 0.03). The distributions of genotypes were in Hardy-Weinberg equilibrium for both cases and controls, and the overall frequency of the Hp1 allele was 38.3%, which is similar to that found in other Western European populations. Conclusions: The results suggest that the Hp2 allele may confer susceptibility to nephropathy in patients with type 1 diabetes.


  • Open Access

    Opiate toxicity in patients with renal failure

    by B R Conway, D G Fogarty, W E Nelson, C C Doherty

    ### Case 1 A 68 year old woman with type 2 diabetes, angina, and obesity had an uncomplicated below knee amputation. Baseline creatinine was 133 μmol/l (estimated glomerular filtration rate 36 ml/min).2 In the first 36 hours after surgery she received 50 mg of morphine and 76 mg of codeine. On the second day she developed oliguria despite intravenous fluid resuscitation, and her serum creatinine rose to 213 μmol/l. She became increasingly drowsy and her respiratory rate fell to 8 breaths/min. Opiate toxicity was suspected after consultation with the on-call nephrologist. She did not respond to 400 μg intravenous naloxone, however, and therefore she was transferred to the regional renal unit. On admission she was drowsy and uncommunicative. Observations showed oxygen saturation 91% on 28% inspired oxygen; respiratory rate 6 breaths/min; pulse 50 beats/min, and blood pressure 132/68 mm Hg. Pupils were pinpoint. Initial investigations detected sodium 130 mmol/l, potassium 7.6 mmol/l, urea 28.4 mmol/l, creatinine 320 μmol/l, pH 7.39, Po2 7.9 kPa, and Pco2 5.9 kPa. Electrocardiogram showed no hyperkalaemic changes. We noticed that the cannula previously used to administer naloxone had tissued. We gave 400 μg of naloxone via a new cannula, …


  • Open Access

    Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis

    by Bryan Conway, Maureen McLaughlin, Peter Sharpe, John Harty

    Background. Patients undergoing chronic haemodialysis frequently have elevated serum cardiac troponin T (cTnT) levels resulting in difficulty in diagnosing acute coronary syndromes (ACS) in these patients. We sought to determine whether: (i) cTnT concentrations were consistent over time; (ii) intradialytic changes in cTnT levels were due to haemoconcentration; (iii) baseline cTnT levels predicted subsequent mortality or ACS. Methods. We measured serial pre- and post-dialysis cTnT concentrations in 75 asymptomatic patients undergoing chronic haemodialysis at baseline, and at 48 h, 8 months and 15 months. At 15 months, we also measured pre- and post-dialysis haematocrit levels in order to adjust the post-dialysis cTnT concentration for the effect of ultrafiltration. Kaplan–Meier survival curves, log-rank tests and Cox models were employed to determine whether baseline cTnT levels predicted death or ACS within 18 months. Results. Thirty-five (47%) patients had a baseline pre-dialysis cTnT concentration in the diagnostic range for an ACS (cTnT ≥ 0.03 µg/l). There was a strong correlation between serial cTnT concentrations in individual patients (PPP = 0.48). Elevated baseline cTnT levels were associated with an increased risk of mortality or ACS at 18 months (P = 0.0015). Conclusion. In asymptomatic patients on haemodialysis, serum cTnT concentrations are frequently elevated, and they rise during dialysis due to haemoconcentration. cTnT levels fluctuate minimally in individual patients in the medium term, therefore annual measurements may be useful reference points in the diagnosis of chest pain and in the prediction of ACS and mortality.


  • Open Access

    Role of -adducin DNA polymorphisms in the genetic predisposition to diabetic nephropathy

    by Bryan R. Conway, Rosalind Martin, Amy-Jayne McKnight, David A. Savage, Hugh R. Brady, Alexander P. Maxwell

    Background. There is substantial evidence for genetic susceptibility to diabetic nephropathy. In particular, genes that predispose to hypertension in the general population may confer susceptibility to nephropathy in patients with diabetes. A Gly460Trp variant in the α-adducin gene has been associated with essential hypertension. Our aim was to screen the α-adducin gene for polymorphisms and to determine if any variants predisposed patients with diabetes to nephropathy. A secondary objective was to assess for association between the Gly460Trp variant and hypertension. Methods. The exons of the α-adducin gene were resequenced in 30 individuals. Selected variants were then genotyped in 155 patients with type 1 diabetes and nephropathy (cases) and 216 persons with type 1 diabetes but no evidence of nephropathy (controls) from Northern Ireland and in 95 cases and 118 controls from the Irish Republic. Results. Eleven polymorphisms were detected, of which six were novel and three caused amino-acid substitutions. The Gly460Trp and a novel Ser617Cys polymorphism were in strong linkage disequilibrium (D' = 0.98). Neither the genotype nor allele frequencies for the Gly460Trp polymorphism (P = 0.89 and 0.93 respectively) or the Ser617Cys polymorphism (P = 0.46 and 0.76) were significantly different between cases and controls when the Northern Ireland and Irish Republic sample groups were combined. Carriage of the 460Trp allele was not significantly associated with systolic or diastolic blood pressure in either the cases (P = 0.48 and 0.06, respectively) or in the controls (P = 0.50 and 0.94, respectively). Conclusions. Variation in the α-adducin gene does not play a major role in the development of nephropathy in persons with type 1 diabetes in the Irish population. Furthermore, the Gly460Trp variant was not associated with hypertension in this population.


  • Open Access

    Association Between Variation in the Actin-Binding Gene Caldesmon and Diabetic Nephropathy in Type 1 Diabetes

    by Bryan R. Conway, A. Peter Maxwell, David A. Savage, Chris C. Patterson, Peter P. Doran, Madeline Murphy, Hugh R. Brady, Damian G. Fogarty

    Dysfunction of the actin cytoskeleton is a key event in the pathogenesis of diabetic nephropathy. We previously reported that certain cytoskeletal genes are upregulated in mesangial cells exposed to a high extracellular glucose concentration. One such gene, caldesmon, lies on chromosome 7q35, a region linked to nephropathy in family studies, making it a candidate susceptibility gene for diabetic nephropathy. We screened all exons, untranslated regions, and a 5-kb region upstream of the gene for variation using denaturing high-performance liquid chromatography technology. An A>G single nucleotide polymorphism (SNP) at position −579 in the promoter region was associated with nephropathy in a case-control study using 393 type 1 diabetic patients from Northern Ireland (odds ratio [OR] 1.38, 95% CI 1.02–1.86, P = 0.03). A similar trend was found in an independent sample from a second center. When the sample groups were combined (n = 606), the association between the −579G allele and nephropathy remained significant (OR 1.35, 1.07–1.70, P = 0.01). The haplotype structure in the surrounding 7-kb region was determined. No single haplotype was more strongly associated with nephropathy than the −579A>G SNP. These results suggest a role for the caldesmon gene in susceptibility to diabetic nephropathy in type 1 diabetes.


    • 1 November 2003
      • Vol. 72  (2) , 86-92

    Impact of serum troponin measurement on triage of chest pain in a district hospital.

    by B Conway, J O'Connor, B McClements

    To evaluate the impact on the clinical service of incorporating cardiac troponin T (cTnT) measurement into the existing chest pain care pathway in our district general hospital. We randomised 200 consecutive patients admitted with acute chest pain, but without ST elevation on ECG, either to our existing chest pain care pathway (pathway 1) or to a new pathway incorporating semi-quantitative cTnT measurement (pathway 2). In comparison with pathway 1, in pathway 2 there was a strong trend towards reduced length of stay (3.13 v 4.36 days, p=0.08), and reduced usage of low molecular weight heparin (LMWH) (4.59 v 5.45 doses per patient, p=0.05). The number of cardiac events at three months in care pathway 1 (14/92) and care pathway 2 (22/108) did not significantly differ, p=0.34. In patients with atypical chest pain, there was a tendency for cardiologists to discharge earlier (1.75 v 2.03 days, p=0.07) and use less LMWH (2.04 v 2.97 doses, p=0.06) than general physicians. In this study, incorporation of cTnT measurement into a chest pain care pathway resulted in a strong trend towards reduced length of hospital stay and LMWH usage.